Saturday 17 October 2026
Export PASG’s income statement to Excel — free account
Passage Bio, Inc.
PASG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.48
0.12
−3.33%
Follow PASG
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 108.79 | 45.04 | 14.98 | 11.02 | 10.74 | 7.22 | 4.07 | 2.07 |
Net Debt/EBITDA |
— | 2.46 | 4.29 | 2.73 | 1.74 | 1.42 | 1.07 | 1.11 | 0.96 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.45 | 0.87 | 0.72 | 0.68 | 0.87 | 0.77 | 0.74 | 0.69 |
Capex/Depreciation |
— | — | (12.63) | (1.15) | (5.93) | (1.18) | (0.09) | (0.02) | 1.37 |
| — | 37.32% | 133.38% | (90.34%) | (59.48%) | (52.35%) | (65.29%) | (75.07%) | (113.78%) | |
| — | (76.33%) | (43.04%) | (44.31%) | (54.28%) | (45.48%) | (51.80%) | (51.21%) | (55.28%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (4,024.99%) | (735.76%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (38.56%) | (27.97%) | (37.56%) | (58.05%) | (67.65%) | (87.30%) | (94.16%) | (158.14%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.41) | (196.36) | (42.56) | (57.18) | (45.37) | (28.65) | (15.59) | (9.56) |
Cash per Share |
— | 0.54 | 750.11 | 157.87 | 118.39 | 69.67 | 41.76 | 24.93 | 14.59 |
Shareholders Equity per Share |
— | (0.27) | (265.59) | 157.82 | 119.47 | 73.99 | 40.66 | 19.90 | 5.91 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.27) | (265.59) | 157.82 | 119.47 | 73.99 | 40.66 | 19.90 | 5.91 |
Free Cash Flow |
— | (18.57) | (41.59) | (82.17) | (152.52) | (123.48) | (78.41) | (47.99) | (30.34) |
Working Capital |
— | 33.09 | 162.09 | 296.01 | 295.57 | 178.69 | 101.62 | 59.45 | 24.68 |
Capital Expenditures |
— | (2.54) | (1.69) | (1.65) | (25.64) | (5.27) | (0.15) | (0.03) | 1.17 |
Net Current Asset Value |
— | 30.88 | (69.09) | 293.89 | 288.65 | 154.86 | 78.70 | 37.66 | 4.24 |
| Other line items | |||||||||
Quick Ratio |
— | 80.98 | 43.16 | 14.40 | 10.70 | 10.33 | 6.99 | 3.96 | 2.01 |
Depreciation/Fixed assets |
— | 0.00 | 0.12 | 0.51 | 0.18 | 0.20 | 0.11 | 0.17 | 0.21 |
Cash ROIC |
— | (146.34%) | (40.53%) | (13.48%) | (24.04%) | (31.58%) | (34.76%) | (34.77%) | (46.63%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.41) | (188.37) | (41.70) | (47.57) | (43.44) | (28.59) | (15.58) | (9.93) |
Capex per Share |
— | 0.00 | (7.99) | (0.85) | (9.61) | (1.94) | (0.05) | (0.01) | 0.37 |
Average Payables |
— | 0.42 | 0.42 | 2.95 | 7.36 | 6.76 | 2.68 | 1.02 | 0.93 |
Average Assets |
— | 16.73 | 106.04 | 253.31 | 341.54 | 299.31 | 197.05 | 126.48 | 82.35 |
Average Common Equity |
— | (34.21) | (34.21) | 124.23 | 311.69 | 260.01 | 156.32 | 86.27 | 40.01 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates